Filtricine, Inc. is a clinical stage biotechnology company focused on developing novel products for cancer care. We are backed by venture capital and located in the San Francisco Bay Area of California. We are developing an innovative way to help patients treat their cancers through our proprietary nutritional regimen of replacement meals. Our lead product is currently being investigated in clinical studies.
Our founders discovered Targeted Nutrients Deprivation during their research at Stanford University. Cancer cells need multiple non-essential amino acids to survive. Those NEAAs are found in all foods we eat. We found a way to formulate foods without these NEAAs while preserving the nutrients our bodies need to thrive. Tality was created for cancer patients to regain control of their lives and get back to living their best life.
You are welcome to join this ongoing clinical trial at Stanford University
Tality is open to all cancer patients willing to try it for 4 weeks at no cost